Omniscient's revolutionary platform, Quicktome®, leverages AI to convert a standard MRI scan into a detailed map of an individual's brain networks. The latest funding round will support continued growth in the US market and product development for expanded indications. SYDNEY, June 11, 2024 (GLOBE NEWSWIRE) -- Omniscient ("o8t®"), pioneering the use of AI to decode the human brain, today announced the conclusion of a successful Series C funding round, bringing total capital raised to US$60 million. This represents the most recent milestone in the company's history of continued growth, with two FDA-cleared products to date. At the intersection of data science and neuroscience, the company stands as a global pioneer in connectomics, utilizing AI to map and analyze an individual's intricate web of brain connections and functions. Among Omniscient's investors are prominent Australian business leaders Will Vicars and Gina Rinehart, underscoring their continued confidence in Omniscient's vision and capabilities. This latest achievement follows Omniscient's successful participation at the 2024 South By Southwest® (SXSW) conference in Austin, Texas, where the ...